Abstract

Delivery of a small RNA to Tumors: From Bench to Bedside

Roel Schaapveld, Chief Executive Officer, InteRNA Technologies BV

Preclinical and early clinical evaluation of an LNP-formulated, chemically-modified tumor suppressor microRNA mimic.